News
RARE
43.85
-0.97%
-0.43
Ultragenyx Pharma Price Target Raised to $61.00/Share From $59.00 by TD Cowen
Dow Jones · 1d ago
Ultragenyx Pharma Is Maintained at Buy by TD Cowen
Dow Jones · 1d ago
TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $61
Benzinga · 1d ago
ULTRAGENYX PHARMACEUTICAL INC <RARE.O>: TD COWEN RAISES TARGET PRICE TO $61 FROM $59
Reuters · 1d ago
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)
TipRanks · 2d ago
First Week of RARE June 21st Options Trading
NASDAQ · 3d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 3d ago
Piper Sandler Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
TipRanks · 3d ago
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical (NASDAQ:RARE) has a 12-month price target of $82.55. The company is a biopharmaceutical company developing drugs for the treatment of rare and rare diseases. 11 analysts have provided ratings for the company in the past three months. The firm has a positive revenue growth rate of 23.27% over the past year.
Benzinga · 3d ago
Ultragenyx Pharma Initiated at Outperform by RBC Capital
Dow Jones · 3d ago
Ultragenyx Pharma Price Target Announced at $77.00/Share by RBC Capital
Dow Jones · 3d ago
RBC Capital Initiates Coverage On Ultragenyx Pharmaceutical with Outperform Rating, Announces Price Target of $77
Benzinga · 3d ago
ULTRAGENYX PHARMACEUTICAL INC <RARE.O>: RBC INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $77
Reuters · 3d ago
Ultragenyx Pharm: Statement of changes in beneficial ownership of securities
Press release · 5d ago
Insiders Could Have Profited By Holding onto Ultragenyx Pharmaceutical Shares Despite 15% Drop
Ultragenyx Pharmaceutical Inc. Insiders sold US$2.3m worth of stock over the last year. The average selling price of US$49.82 is lower than the current share price. Insiders in Ultragenyx pharmaceutical didn't buy any shares in the lastyear. The company has a high insider ownership of 3.9% of the company. But the last three months saw significant insider selling at Ultrageny Pharmaceutical.
Simply Wall St · 04/18 11:29
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
TipRanks · 04/18 10:10
Buy Rating on Ultragenyx Pharmaceutical Bolstered by GTX-102’s Promise and Positive Valuation Outlook
TipRanks · 04/18 04:26
Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
Benzinga · 04/17 17:20
3 Best Stocks to Buy Now, 4/17/2024, According to Top Analysts 
TipRanks · 04/17 11:45
As more rare disease therapies launch, their prices are rising
Therapies that treat rare diseases are among the most expensive treatments for patients. The most expensive medicine in the world, Lenmeldy, comes with a wholesale price of $4.25M. Cantor Fitzgerald says the prices of rare disease therapies have been increasing since 2021.
Seeking Alpha · 04/16 16:22
More
Webull provides a variety of real-time RARE stock news. You can receive the latest news about Ultragenyx Pharm through multiple platforms. This information may help you make smarter investment decisions.
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.